Carisma Therapeutics IncNASDAQ:CARMNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8510
- TODAY'S CHANGE (%)0.0031 (0.3715%)
- Bid / Lots0.8500/ 7
- Ask / Lots0.8538/ 2
- Open / Previous Close0.8478 / 0.8478
- Day Range
- 52 Week Range
- Volume52,244
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CARM |
|---|---|---|
| 09:32 ET | 1855 | 0.8478 |
| 09:33 ET | 1600 | 0.8545 |
| 09:39 ET | 1611 | 0.8498 |
| 09:42 ET | 845 | 0.8478 |
| 09:46 ET | 400 | 0.8547 |
| 09:50 ET | 1428 | 0.8548 |
| 09:51 ET | 7200 | 0.85 |
| 09:53 ET | 4872 | 0.8476 |
| 10:00 ET | 100 | 0.8498 |
| 10:02 ET | 250 | 0.8433 |
| 10:04 ET | 500 | 0.8497 |
| 10:06 ET | 117 | 0.8498 |
| 10:09 ET | 2546 | 0.8584 |
| 10:11 ET | 2500 | 0.85 |
| 10:15 ET | 100 | 0.8501 |
| 10:20 ET | 3412 | 0.8593 |
| 10:22 ET | 6092 | 0.8592 |
| 10:29 ET | 6337 | 0.85 |
| 10:33 ET | 299 | 0.8573 |
| 10:42 ET | 1000 | 0.85 |
| 10:47 ET | 565 | 0.8434 |
| 10:51 ET | 367 | 0.8435 |
| 11:00 ET | 100 | 0.8435 |
| 11:02 ET | 400 | 0.8498 |
| 11:14 ET | 900 | 0.85 |
| 11:18 ET | 800 | 0.8497 |
| 11:23 ET | 100 | 0.8539 |
| 11:30 ET | 1100 | 0.85095 |
Nov 18, 2024
DJ Carisma Therapeutics Is Maintained at Buy by D. Boral Capital, from 4:54PM ET on Monday Nov 18, 2024 by Dow Jones
4:54PM ET on Monday Nov 18, 2024 by Dow Jones
Nov 17, 2024
Nov 11, 2024
DJ Carisma Therapeutics Is Maintained at Buy by D. Boral Capital, from 5:20PM ET on Monday Nov 11, 2024 by Dow Jones
5:20PM ET on Monday Nov 11, 2024 by Dow Jones
Nov 8, 2024
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma, from 7:30AM ET on Friday Nov 08, 2024 by Dow Jones
7:30AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
DJ Carisma Therapeutics Is Maintained at Buy by EF Hutton, from 8:43AM ET on Thursday Nov 07, 2024 by Dow Jones
8:43AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Carisma Therapeutics Inc | 35.4M | -0.5x | --- |
Curis Inc | 34.0M | -0.5x | --- |
Collplant Biotechnologies Ltd | 47.7M | -2.7x | --- |
HOOKIPA Pharma Inc | 27.7M | -0.6x | --- |
Aligos Therapeutics Inc | 71.0M | -1.0x | --- |
Affimed NV | 40.2M | -0.6x | --- |
Company Information
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Contact Information
- Headquarters
- 3025 Market Street Ste 140PHILADELPHIA, PA, United States 19104
- Phone
- 617-444-8550
- Fax
- 617-858-0911
Executives
- Independent Non-Executive Chairman of the Board
- Sanford Zweifach
- President, Chief Executive Officer, Director
- Steven Kelly
- Chief Financial Officer
- Richard Morris
- Chief Scientific Officer
- Michael Klichinsky
- General Counsel, Corporate Secretary
- Eric Siegel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $35.4M |
|---|---|
Revenue (TTM) | $20.3M |
Shares Outstanding | 41.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-1.56 |
Book Value | $0.65 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 1.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -329.46% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
